| IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance M Walsh, A Jordan, L Schäfer, J Joha, B Heapes, M Noonan, W Gallagher, ... Clinical Genitourinary Cancer 22 (3), 102063, 2024 | | 2024 |
| Abstract A069: High-resolution volumetric imaging of primary and metastatic high-grade serous ovarian cancer explants AE Connor, J Lysaght, DJ Brennan, JC Simpson, AS Perry Cancer Research 84 (5_Supplement_2), A069-A069, 2024 | | 2024 |
| Abstract B019: Investigating Cannabis sativa bioactive compounds as an anti-cancer treatment in high-grade serous ovarian cancer C Hughes, R Magee, W Gallagher, S Schilling, A Perry Cancer Research 84 (5_Supplement_2), B019-B019, 2024 | | 2024 |
| Investigating Cannabis sativa bioactive compounds as an anti-cancer treatment in high-grade serous ovarian cancer C Hughes, R Magee, W Gallagher, S Schilling, A Perry CANCER RESEARCH 84 (5), 2024 | | 2024 |
| Deciphering epigenetic regulation of enhancers in high‐risk prostate cancer AV Tuzova, B Moran, NM Russell, S Das, F Delahaye, R Silva, C Barrett, ... Genes, Chromosomes and Cancer 63 (2), e23218, 2024 | | 2024 |
| Involving patients in healthcare research is well documented but can it work in lab-based research? AE Connor, C Hughes, L Schäfer, L McNally, DO Raw, K Bahramian, ... Research Involvement and Engagement 9 (1), 90, 2023 | | 2023 |
| Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells E O’Reilly, K Khalifa, J Cosgrave, H Azam, M Prencipe, JC Simpson, ... Journal of Natural Products 86 (9), 2151-2161, 2023 | 2 | 2023 |
| Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer R Silva, K Glennon, M Metoudi, B Moran, S Salta, K Slattery, A Treacy, ... International Journal of Cancer 153 (1), 120-132, 2023 | 3 | 2023 |
| Epigenetic insights into diagnostic and therapeutic applications E Fratta, C Jeronimo, AS Perry, SG Pattenden Frontiers in Oncology 13, 2023 | | 2023 |
| Therapeutic applications of the prostate cancer epigenome JM Cosgrave, AS Perry Epigenetic Cancer Therapy, 301-337, 2023 | | 2023 |
| EP004/# 741 DNA methylation landscape as a potential player in acquired-drug resistance in ovarian cancer R Silva, K Glennon, M Metoudi, B Moran, S Salta, K Slattery, A Treacy, ... International Journal of Gynecologic Cancer 32 (Suppl 3), 2022 | | 2022 |
| A family of mixture models for beta valued DNA methylation data K Majumdar, R Silva, AS Perry, RW Watson, A Rau, F Jaffrezic, ... arXiv preprint arXiv:2211.01938, 2022 | | 2022 |
| betaclust: a family of mixture models for beta valued DNA methylation data K Majumdar, R Silva, AS Perry, RW Watson, TB Murphy, IC Gormley arXiv preprint arXiv:2211.01938, 2022 | | 2022 |
| Active surveillance for men younger than 60 years or with intermediate-risk localized prostate cancer. Descriptive analyses of clinical practice in the Movember GAP3 initiative S Remmers, J Helleman, D Nieboer, B Trock, ME Hyndman, CM Moore, ... European Urology Open Science 41, 126-133, 2022 | 7 | 2022 |
| Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the GAP 3 global consortium database KR Beckmann, CH Bangma, J Helleman, A Bjartell, PR Carroll, T Morgan, ... The Prostate 82 (7), 876-879, 2022 | 1 | 2022 |
| Plant-derived cannabinoids as anticancer agents EM O’Reilly, JM Cosgrave, WM Gallagher, AS Perry Trends in cancer 8 (5), 350-357, 2022 | 8 | 2022 |
| Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report R Silva, B Moran, S Das, N Mulligan, M Doughty, A Treacy, K Sheahan, ... Case Reports in Women's Health 34, e00395, 2022 | 2 | 2022 |
| Prostate cancer patients under active surveillance with a suspicious magnetic resonance imaging finding are at increased risk of needing treatment: results of the Movember … J Olivier, W Li, D Nieboer, J Helleman, M Roobol, V Gnanapragasam, ... European Urology Open Science 35, 59-67, 2022 | 13 | 2022 |
| Epigenetics and precision medicine in prostate cancer AC Jordan, M Prencipe, R Silva, WM Gallagher, AS Perry Epigenetics in Precision Medicine, 69-108, 2022 | | 2022 |
| Comparison of characteristics, follow-up and outcomes of active surveillance for prostate cancer according to ethnicity in the GAP3 global consortium database K Beckmann, A Santaolalla, J Helleman, P Carroll, BH Chung, LS Lee, ... European Urology Open Science 34, 47-54, 2021 | 2 | 2021 |
